💪 Immunotherapy Power Duo: Nivolumab + Ipilimumab vs. TKIs in HCC

from Dr RR Baliga's "Got Knowledge Doc" Podkast · host MasterMedFacts LLC

🚀 New Breakthrough in Liver Cancer! 🌟 The CheckMate 9DW trial shows that Nivolumab + Ipilimumab significantly improves survival in unresectable #HCC compared to lenvatinib/sorafenib! 🧬💪 #Immunotherapy #CancerResearch #LiverCancer #Oncology 💉

Episode metadata supplied by the publisher feed · Published May 16, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

💪 Immunotherapy Power Duo: Nivolumab + Ipilimumab vs. TKIs in HCC

0:00 4:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Dr RR Baliga's "Got Knowledge Doc" Podkast?

This episode is 4 minutes long.

When was this Dr RR Baliga's "Got Knowledge Doc" Podkast episode published?

This episode was published on May 16, 2025.

Can I download this Dr RR Baliga's "Got Knowledge Doc" Podkast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!